The next focusIR Investor Webinar takes places on 14th May with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAMYT.L Regulatory News (AMYT)

  • There is currently no data for AMYT

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Final Results

30 Sep 2009 07:00

30 September 2009 Sterling Green Group plc ("Sterling" or "the Company") Final Results for the year ended 31 March 2009

CHAIRMAN'S STATEMENT

Introduction and review of activities

I am pleased to present the financial statements of Sterling Green Group plc and its subsidiaries ("the Group") covering the year ended 31 March 2009.

Results and dividends

Revenue for the year ended 31 March 2009 was 1,966,000 (15 month period ended31 March 2008 - 1,309,000). Revenue was made up of 1,609,000 (15 month periodended 31 March 2008 - 970,000) from debt management services and 357,000 (15month period ended 31 March 2008 - 339,000) relating to mortgage business.

The Group loss after taxation for the year amounted to 347,000 (15 month period ended 31 March 2008 - 1,648,000). The Directors are not able to recommend the payment of a dividend.

Trading review

In the Chairman's Statement dated 30 September 2008 which accompanied the 2008financial statements, I reported that the Board had overseen a significantreduction in the Group's operational costs, following amongst other things, astreamlining of the senior management team.Those events have enabled the Group to show, at an operating level, a profit of 31,000 for the second half of the financial year ended 31 March 2009, havingalready reported an interim operating loss for the 6 month period ended 30September 2008 of 352,000. This turnaround reflects the combination of reducedoperating costs and increased revenues.

Current performance and future developments

The Group has started the new financial year as a much more streamlinedbusiness, with a lower overhead base and improving recurring revenues in itsdebt management business. The current economic climate in the UK is enablingthe Group to increase its customer numbers at a faster rate than that seenduring the year ended 31 March 2009. At the present time, the Group already hasin excess of 3,000 live clients and the Board believe that the resulting risinglevels of recurring income give the Group a solid foundation on which to builda profitable future.The Group's working capital position remains challenging. The Group iscurrently operating within its existing borrowing facilities and based onforecasts prepared for the period ended 31 March 2011 management remainconfident that this situation will continue throughout the forecast period.Should those forecasts not be achieved, however, the Group will need to reduceits operating costs further and will be required to consider raising additionalcapital through the issue of further equity or through increased bank or otherfacilities.Further regulation in the UK debt management industry appears inevitable ascompetition in the sector continues to increase. The Board will welcome theintroduction of any new regulation and considers that the Group's existingprocedures and systems meet with industry best practice. The introduction ofnew regulation often leads to acquisition opportunities and the Board considersthat the acquisition of debt management businesses or debt managementportfolios remains a viable option for increasing Group revenues andprofitability in the short term.J M EdelsonChairman29 September 2009Further Enquiries:Sterling Green Group plc Tel: +44 161 975 5757 Michael Edelson

John East & Partners Limited, a subsidiary of Merchant Tel: +44 20 7628 2200

Securities Plc David Worlidge / Simon Clements

CONSOLIDATED INCOME STATEMENT

FOR THE YEAR ENDED 31 MARCH 2009

Note Year ended Period ended 31 March 31 March 2009 2008 GBP000 GBP000 Revenue 1,966 1,309 Cost of sales (1,069) (1,423) Gross profit/(loss) 897 (114) Administrative expenses (1,218) (1,538) Loss from operations (321) (1,652) Investment income 5 24 Finance costs (49) (20) Loss on ordinary activities before taxation (365) (1,648) Income tax credit 2 18 - Loss on ordinary activities after taxation (347)

(1,648)

attributable to equity holders of the

parent Loss per share - basic and diluted 3 (0.12p) (0.70p)CONSOLIDATED BALANCE SHEETAS AT 31 MARCH 2009 Note 2009 2008 GBP000 GBP000 Non-current assets Intangible assets 1,115 1,115 Property, plant and equipment 209 309 Total non-current assets 1,324 1,424 Current assets Trade and other receivables 142 141 Cash and cash equivalents 4 182 180 Total current assets 324 321 Current liabilities Trade and other payables (319) (318) Current tax liabilities - (18) Borrowings (86) (284) Total current liabilities (405) (620) Net current liabilities (81) (299) Non-current liabilities Borrowings (318) (153) Total non-current liabilities (318) (153) Net assets 925 972 Equity Called up share capital 288 280 Share premium account 1,710 1,518 Share capital to be issued 100 - Capital reserve 6 6 Other reserve 891 891 Accumulated losses (2,070) (1,723) Total equity 925 972

CONSOLIDATED CASH FLOW STATEMENT

FOR THE YEAR ENDED 31 MARCH 2009

Note Year ended Period ended 31 March 31 March 2009 2008 GBP000 GBP000

Cash flows used in operating activities

Loss before tax (365) (1,648) Adjustments for:

Depreciation of property, plant and equipment 101

113 Investment income (5) (24) Finance costs 49 20 Operating cash flows before movement in (220) (1,539)working capital

Increase in trade and other receivables (1)

(46)

Increase in trade and other payables 1

88

Net cash used in operating activities (220)

(1,497)

Cash flows from investing activities

Investment income received 5 24 Purchase of property, plant and equipment (1)

(389)

Acquisition of subsidiary, net of cash -

(29)acquired Net cash from/(used in) investing activities 4

(394)

Cash flows from financing activities Capital element of lease payments (85)

(68) Finance leases entered into - 307 Loans advanced 250 - Issue of ordinary share capital, net of costs 200

1,593

Proceeds in advance of issue of share capital 100

- Finance costs paid (49) (20) Net cash from financing activities 416

1,812

Net increase/(decrease) in cash and cash 200

(79)equivalents

Cash and cash equivalents at the start of the (18)

61year

Cash and cash equivalents at the end of the 4 182

(18)

year

CONSOLIDATED STATEMENT OF CHANGES IN EQUITY

FOR THE YEAR ENDED 31 MARCH 2009

Attributable to equity holders of the parent Share Share Share Capital Other Accumulated Total capital premium capital reserve reserve losses account to be issued GBP000 GBP000 GBP000 GBP000 GBP000 GBP000 GBP000

At 1 January 2007 85 - - 6 - (75)

16 Loss for the - - - - - (1,648) (1,648)period Issue of share 195 1,677 - - 891 - 2,763capital Costs of share - (159) - - - - (159)issue At 31 March 2008 280 1,518 - 6 891 (1,723) 972 Loss for the year - - - - - (347) (347) Issue of share 8 192 - - - - 200capital Share capital to - - 100 - - - 100be issued

At 31 March 2009 288 1,710 100 6 891 (2,070) 925

Other reserve

The other reserve is a merger reserve created on the acquisition of Sterling Green Limited.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

FOR THE YEAR ENDED 31 MARCH 2009

1. BASIS OF PREPARATION

The financial information set out above does not constitute the Company'sstatutory financial statements for the period ended 31 March 2008 and for theyear ended 31 March 2009, but is derived from those financial statements. TheAuditors have reported on those financial statements; their reports wereunqualified and did not contain statements under the Companies Act 1985,sections 237(2) or (3).The financial statements from which the financial information set out above isderived have been prepared in accordance with International Financial ReportingStandards as adopted by the European Union (IFRS).The Board has considered the Group's financial position and trading prospectsusing detailed forecasts covering the period ending 31 March 2011. Thoseforecasts incorporate the current drawn down loan facility which is confirmedas available until 30 September 2010. There are no financial covenants attachedto that facility. Accordingly, the Board considers that there will be nobreaches of financial covenants during the period to 30 September 2010. Havingmade appropriate consideration, the Board believes that it has adequateresources to continue trading for the foreseeable future, and accordingly, thegoing concern basis has been adopted in preparing these financial statements.2. INCOME TAX CREDIT Year ended Period ended 31 March 31 March 2009 2008 GBP000 GBP000 Current tax: Income tax credit 18 -

The income tax credit is calculated at 28% (period ended 31 March 2008 - 30%) of the estimated assessable loss for the year.

The income tax credit for the year can be reconciled to the income statement asfollows: Year ended Period ended 31 March 31 March 2009 2008 GBP000 GBP000 Loss before tax (365) (1,648) Loss on ordinary activities multiplied by the (102)

(494)

relevant standard rate of income tax in the UK of

28% (2008 - 30%) Effect of:

Expenses not deductible for tax purposes 6

18

Depreciation for year in excess of capital 28

34allowances Utilisation of losses 18 - Losses carried forward 68 442

Current tax credit for the year 18

-

Unrecognised deferred tax assets

The following deferred tax assets have not been brought into account as assets: 2009 2008 GBP000 GBP000 Tax losses 476 333 Temporary differences 56 233. LOSS PER SHARE

The calculation of basic loss per share is based on the following:

Basic Year ended Period ended 31 March 31 March 2009 2008 Loss for the year ( 000) (347) (1,648) Weighted average number of shares 287,569,637 235,986,036 Loss per share (pence) (0.12) (0.70)Diluted loss per share is calculated by adjusting the weighted average numberof ordinary shares in issue assuming conversion of all dilutive potentialordinary shares. During the year the Company's potential ordinary sharesconsist of share options, warrants and deferred consideration. Due to losses inthe current year and preceding period there are no dilutive ordinary shares.

4. NOTES TO THE CASHFLOW STATEMENT

4.1 Cash and cash equivalents

Cash and cash equivalents consist of bank balances and bank overdrafts. Cashand cash equivalents included in the cash flow statement comprise the followingbalance sheet amounts: 2009 2008 GBP000 GBP000 Cash at bank 182 180 Bank overdrafts - (198) Cash and cash equivalents 182 (18)

4.2 Significant non-cash transactions

During the comparative period the Group acquired property, plant and equipment with a total cost of 340,000 of which 307,000 was acquired by means of finance leases.

Part of the purchase price for the acquisition of Sterling Green Limited duringthe comparative period comprised ordinary shares. The fair value of the sharesissued was 950,000.5. DIVIDEND

The directors are not able to recommend the payment of a dividend.

6. COPIES OF THE REPORT & ACCOUNTS

Copies of the Report & Accounts will be posted to shareholders shortly and arealso available from the Company's registered office at Number 14, TheEmbankment, Vale Road, Heaton Mersey, Stockport, Cheshire SK4 3GN and from theCompany's website www.sterlinggreen.co.uk.

vendor
Date   Source Headline
6th Jan 20225:30 pmRNSAmryt Pharma
6th Jan 20227:00 amGNWKey Dates for AIM Delisting
4th Jan 202212:00 pmGNWThe Lancet Diabetes & Endocrinology Publishes Positive Results for the MPOWERED Phase 3 Trial for Mycapssa® (oral octreotide) in Acromegaly Patients
4th Jan 20227:00 amGNWTotal Voting Rights
1st Dec 20217:00 amGNWTotal Voting Rights
30th Nov 20217:00 amGNWDirector/PDMR Shareholding
23rd Nov 202112:00 pmGNWAmryt Provides Update on Regulatory Review Process for Oleogel-S10
22nd Nov 20217:00 amGNWAmryt Announces the Cancellation of Admission of its Ordinary Shares to Trading on AIM
3rd Nov 202111:00 amGNWAmryt Reports Strong Q3 2021 Results
1st Nov 20211:00 pmGNWTotal Voting Rights
1st Nov 20217:00 amRNSAmryt Supports Acromegaly Awareness Day
22nd Oct 20217:00 amRNSAmryt Supports Global EB Awareness Week 2021
20th Oct 202112:00 pmGNWAmryt to Report Q3 2021 Results and Host Conference Call & Webcast on November 3
19th Oct 202112:00 pmGNWAmryt Announces New Patents for Oleogel-S10 and Mycapssa®
23rd Sep 202112:00 pmRNSAmryt Supports Global FH Awareness Day
13th Sep 202112:00 pmGNWAmryt Raises Full Year 2021 Revenue Guidance to $220M - $225M
1st Sep 20217:00 amGNWTotal Voting Rights
19th Aug 20217:00 amGNWAmryt Issues Ordinary Shares and Total Voting Rights
13th Aug 20211:23 pmRNSHolding(s) in Company - Replacement
11th Aug 202111:30 amRNSHoldings in Company
11th Aug 202110:36 amRNSHolding(s) in Company
10th Aug 20212:20 pmGNWDirector/PDMR Shareholding
10th Aug 20219:53 amRNSHolding(s) in Company
9th Aug 202112:00 pmGNWAmryt Virtual Capital Markets Event - September 13, 2021 – 1000-1200 EDT
6th Aug 202112:00 pmGNWAmryt Reports Record Q2 2021 Results and Raises FY 2021 Guidance
5th Aug 20213:50 pmGNWAmryt Successfully Completes Acquisition of Chiasma, Inc., Board Appointments, Issues Ordinary Shares and Total Voting Rights
28th Jul 20213:00 pmGNWResult of General Meetings
12th Jul 202112:00 pmGNWAmryt to Report Q2 2021 Results and Host Conference Call & Webcast on August 6
28th Jun 202112:00 pmGNWPublication of Circular to Amryt Shareholders in relation to the acquisition of Chiasma, Inc., and posting of Annual Report and Notices of General Meetings
15th Jun 202111:45 amGNWAmryt Pharma Announces Filing of Preliminary Registration Statement on Form F-4 in Connection with Its Proposed Acquisition of Chiasma, Inc.
7th Jun 202112:00 pmGNWFDA confirms NDA for Oleogel-S10 will not require an Advisory Committee Meeting
3rd Jun 20217:00 amGNWFDA Grants Priority Review for New Drug Application for Oleogel-S10 for the Treatment of Epidermolysis Bullosa
2nd Jun 20211:30 pmGNWAmryt Announces FDA Acceptance of New Drug Application for Oleogel-S10 for the Treatment of Epidermolysis Bullosa
5th May 20214:41 pmRNSSecond Price Monitoring Extn
5th May 20214:35 pmRNSPrice Monitoring Extension
5th May 202112:05 pmGNWAmryt Reports Record Q1 2021 Financial and Operating Results
5th May 202112:00 pmGNWAmryt Pharma to Acquire Chiasma, Inc. to Further Strengthen Global Leadership in Rare and Orphan Diseases
15th Apr 202112:00 pmGNWAmryt to Report Q1 2021 Results and Host Conference Call & Webcast on May 5
6th Apr 20217:00 amGNWAmryt Announces the Appointment of Sheila Frame as President Americas
31st Mar 202111:00 amRNSAmryt Supports World Lipodystrophy Day
31st Mar 20217:00 amGNWAmryt Submits a New Drug Application to the US Food and Drug Administration for Oleogel-S10* (Filsuvez®)
30th Mar 20217:00 amGNWAmryt Announces Results from an Investigator Sponsored Study of Lomitapide in FCS
29th Mar 20217:00 amGNWAmryt Announces Validation of its MAA by the EMA for Oleogel-S10* (Filsuvez®)
23rd Mar 20217:00 amGNWAmryt Receives Positive Feedback from the FDA on the Path Forward for Myalept® (metreleptin) Indication in Partial Lipodystrophy
22nd Mar 20217:00 amGNWAmryt Receives Reimbursement Approval from the French Ministry of Social Affairs and Health for Myalepta® (metreleptin)
15th Mar 202110:00 amGNWDirector/PDMR Shareholding
12th Mar 20217:00 amGNWExercise of Options and Total Voting Rights
11th Mar 202111:30 amGNWExercise of Warrants & Issue of Ordinary Shares and Total Voting Rights
8th Mar 20216:00 pmGNWDirector/PDMR Shareholding
8th Mar 20217:00 amGNWAmryt and Medison Pharma Sign Distribution Agreement for Myalepta® (metreleptin) in Canada

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.